April 22, 2024
Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson’s Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Company unveils Parkinson’s disease associated with GBA mutations (PD-GBA) program; two oral presentations feature new data from Capsida’s wholly owned programs in PD-GBA and…
0 Comments9 Minutes
February 21, 2024
Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
0 Comments2 Minutes
June 2, 2023
Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy
Preclinical data show IV administration of a next-generation gene therapy produced dose-dependent replacement of syntaxin-binding protein 1 (STXBP1) throughout the brain, with…
0 Comments5 Minutes
February 23, 2023
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
AbbVie (NYSE: ABBV) and Capsida Biotherapeutics Inc. ("Capsida") today announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet…
0 Comments6 Minutes
January 18, 2023
Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer
0 Comments4 Minutes
May 18, 2022
Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Platform utilizes combinatorial engineering and automation to screen in high-throughput, generating capsids greatly improved over AAV9 in CNS efficiency and specificity. Process…
0 Comments10 Minutes
May 17, 2022
Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Preclinical results demonstrate proof-of-concept of early generation AAV-engineered capsid in MPSII pilot program. Data from capsid engineering platform show greater than 100-fold…
0 Comments9 Minutes
July 22, 2021
Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing
0 Comments4 Minutes
May 12, 2021
Capsida Appoints Swati Tole, M.D., as Chief Medical Officer
Capsida Biotherapeutics Inc., a biotechnology company creating a new class of targeted gene therapies using its next-generation adeno-associated virus (AAV) engineering and cargo…
0 Comments6 Minutes
April 29, 2021
Capsida Biotherapeutics Debuts with $140 Million of Capital
Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an…
0 Comments11 Minutes